DEA Grants Pharmaceutical Company Monopoly on Medical CBD

by Carey Wedler News circulated recently that the DEA had rescheduled cannabidiol (CBD), the nonpsychoactive ingredient in cannabis, but the technicalities of the agency’s decision actually show...